Bintrafusp alfa, the cancer immunotherapy being co-developed by Merck KGaA and GlaxoSmithKline, has been hit by a third clinical trial failure, casting doubt on the future of the potentially multi-billion dollar alliance.
But both companies are likely to remain patient for now, as the broad trial program against a range of hard-to-treat...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?